Pseudomonas aeruginosa (P. aeruginosa) is a rod-shaped, gram-negative aerobic bacterium. It is a primary cause of hospital-acquired infections. P. aeruginosa is primarily a nosocomial pathogen. It also acts as an opportunistic pathogen, which can only infect an immunocompromised host, due to an underlying disease or drug. Although P. aeruginosa can cause damage to virtually any tissue in the body, it almost never affects the tissues of healthy individuals. It is a problematic pathogen in hospitals; infect individuals with cancer, burn wounds, catheters and cystic fibrosis. P. aeruginosa is best known for its resistance to a wide range of antibiotics. In its planktonic form, P. aeruginosa has been found to have many virulence factors. However, P. aeruginosa within biofilms has been found to have 1,000 times greater antibiotic resistance than its planktonic counterparts [4]. Infections caused by bacterial biofilms are very persistent and very difficult to treat. Biofilms have been partially linked to the persistence of P. aeruginosa in cystic fibrosis (CF) infections. In recent years, several treatment methods have been developed to prevent chronic P. aeruginosa biofilm infections. As a result of these methods, chronic P. aeruginosa infections, which were once very common in children with cystic fibrosis, are rarely acquired during childhood and are more predominant in adults with cystic fibrosis [5].INTRODUCTIONP. aeruginosa is a nosocomial opportunistic pathogen highly resistant to antimicrobial agents. These are closely associated medical conditions such as periodontal disease, osteomyelitis and cystic fibrosis. Resistance to many antibiotics is a well-known property of bacterial biofilms. Biofilms are dense… middle of the paper… as chronic P. aeruginosa infections, once prevalent in children with cystic fibrosis, no longer infect most cystic fibrosis patients in childhood. Treatment of chronic P. aeruginosa infections in children with cystic fibrosis. CF LungsChronic suppressive antibiotic therapy is the recommended treatment of chronic P. aeruginosa infections in the CF airways. This treatment method consists of daily use of nebulized tobramycin or colistin for the rest of the patient's life, along with a combination therapy consisting of two antibiotics, administered intravenously, every three months for two weeks[6]. Additionally, azithromycin and DNase are taken daily. Because chronic suppressive antibiotic therapy has been shown to prolong the life of cystic fibrosis patients and delay the weakening of lung function, some aspects of this therapy are consistently used in the treatment of biofilm infections in other areas of the body..[6]